Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

479P - Difference gene mutations among CRC patients with MSS and MSI-H types in China

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Jianjun Yang

Citation

Annals of Oncology (2021) 32 (suppl_5): S530-S582. 10.1016/annonc/annonc698

Authors

J. Yang1, G. Xu2, J. Zheng2, Y. Wang2, S. Wang2, G. Li2, W. Duan3, H. Zhang4, D. Huang5

Author affiliations

  • 1 Department Of Digestive Surgery, State Key Laboratory of Cancer Biology,National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, 070001 - Xi’an/CN
  • 2 Department Of Digestive Surgery, State Key Laboratory of Cancer Biology,National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, 070001 - Xian/CN
  • 3 The Medical Department, 3D Medicines, 201100 - Shanghai/CN
  • 4 The Medical Department, 3D Medicines, 650051 - Kunming/CN
  • 5 The Medical Department, 3D Medicines, 400000 - Chongqing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 479P

Background

Some studies have researched colorectal cancer patients with MSS and MSI-H and indicated the differences between these two phenotype gene mutations, but because there are fewer subjects, they are prone to bias. And this type of research is rarely studied in the Chinese population, so this abstract reports a large-scale population study of this type in Chinese patients.

Methods

The formalin-fixed paraffin-embedded (FFPE) tissues of 6603 patients with CRC who underwent next-generation sequencing (NGS) from Jan, 2019 to Apr, 2021 in 3DMed Clinical Laboratory Inc. were investigated in this study. These patients are still being followed up. Statistical analysis was performed using Microsoft Office Excel (2013).

Results

7.9% (522/6603) patients with MSI-H status, MSI-H tumor and MSS tumors showed striking gene mutation differences. Among the 16 genes with the highest mutation rate, APC TP53 KRAS PIK3CA FBXW7 mutations appear in both MSI-H and MSS patients. But the mutation rates of these genes vary greatly (50.6% VS 79.6%, 25.5% VS 75.6%, 48.7% VS 53.9%, 43.1% VS 15.8%, 23.2% VS 11.9% respectively). Among the top 16 mutated genes, ARID1 (54.2%) mutation with the highest rate is only mutated in MSI-H patients. There are other gene mutations, including TGFBR2 (42.7%), MSH6 (40.8%), KMT2C (37.5%), MSH3 (35.1%), RNF43 (34.5), RAD50 (32.6%), MLH1 (28.7%), BRCA2 (28.4%), ATR (22.8), CTNNB1 (19.3%), which have hugely higher mutation rates than MSS patients. It is worth noting that the mutation rate of TP53 in MSS patients is absolutely higher than that in MSI-H patients.

Conclusions

There are complete differences in gene mutations between MSI-H patients and MSS patients in the Chinese population, especially ARID1, TP53, PIK3CA, TGFBR2, KMT2C, RNF43, RAD50, BRCA2, ATR, CTNNB1, which are of great significance for accurate patient stratification and treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.